目的:澳大利亚育龄女性诊断出子宫肌瘤的估计患病率和发病率是多少?
结论:估计7.3%的澳大利亚女性在45-49岁时诊断出子宫肌瘤,年龄特异性发病率在40-44岁女性中最高(每1000人年5.0例)。
背景:子宫肌瘤与高症状负担相关,可能影响整体健康和生活质量。不同国家的研究表明,子宫肌瘤的患病率(4.5-68%)和发病率(2.2-37.5/1000人年)差异很大。这可以部分解释为调查的类型,案例确定方法,或者研究人群的年龄范围,有必要报告针对具体国家的估计数。
方法:这项观察性前瞻性队列研究使用自我报告调查和相关管理数据(2000-2022年)包括8066名女性,出生于1973年至1978年,在澳大利亚妇女健康纵向研究。
方法:结合自我报告调查和关联的行政卫生数据(医院,急诊科,医疗保险福利计划,和药物福利计划)用于识别在2000年至2022年之间诊断出子宫肌瘤的女性。
结果:在8066名澳大利亚女性中,随访了22年,估计有7.3%的女性(95%CI6.9,7.6)在45~49岁时诊断为子宫肌瘤.发病率随着年龄的增长而增加,在40-44岁的女性中最高(每1000人年5.0例,95%CI4.3,5.7例/1000人年)。患有子宫肌瘤的女性更有可能经历沉重或痛苦的时期。他们也更有可能报告铁水平低,子宫内膜异位症,以及自我评估的健康状况不佳,并每年对其全科医生进行两次或更多次访问。
结论:我们的估计是基于医生对肌瘤的诊断或治疗的自我报告和/或与治疗和手术管理记录相关的数据。这主要捕获有症状的肌瘤女性,但有可能对无症状女性进行错误分类,并低估总体患病率和发病率。此外,关于子宫肌瘤的问题只在妇女37-42岁到43-48岁的调查中被问到,因此,年龄较小的病例可能被低估了(特别是在症状较不严重的女性中),因为这些病例只能通过数据链接来确定。
结论:这是澳大利亚育龄妇女子宫肌瘤患病率和发病率的首次基于人群的估计。建立这些初步估计将有助于为澳大利亚的卫生政策和医疗保健提供信息。
背景:ALSWH由澳大利亚政府卫生和老年护理部门资助。L.FW.由澳大利亚国家卫生和医学研究委员会(NHMRC)研究卓越中心资助(APP1153420)和G.D.M.由NHMRC领导奖学金(APP2009577)支持。资助机构在设计中没有发挥作用,收藏,分析或解释数据,手稿的写作,或决定将手稿提交出版。没有竞争的利益。
背景:不适用。
OBJECTIVE: What is the estimated prevalence and incidence of uterine fibroids diagnosed in Australian women of reproductive age?
CONCLUSIONS: An estimated 7.3% of Australian women had a diagnosis of uterine fibroids by the age of 45-49 years, with age-specific incidence highest in women aged 40-44 years (5.0 cases per 1000 person-years).
BACKGROUND: Uterine fibroids are associated with a high symptom burden and may affect overall health and quality of life. Studies in different countries show a wide variation in both the prevalence (4.5-68%) and incidence (2.2-37.5 per 1000 person-years) of uterine fibroids, which may be partly explained by the type of investigation, method of case ascertainment, or the age range of the
study population, necessitating the reporting of country-specific estimates.
METHODS: This observational prospective cohort
study using self-report survey and linked administrative data (2000-2022) included 8066 women, born between 1973 and 1978, in the Australian Longitudinal
Study on Women\'s Health.
METHODS: A combination of self-report survey and linked administrative health data (hospital, emergency department, the Medicare Benefits Schedule, and the Pharmaceutical Benefits Scheme) were used to identify women with a report of a diagnosis of uterine fibroids between 2000 and 2022.
RESULTS: Of the 8066 Australian women followed for 22 years, an estimated 7.3% of women (95% CI 6.9, 7.6) had a diagnosis of uterine fibroids by the age of 45-49 years. The incidence increased with age and was highest in women aged 40-44 years (5.0 cases per 1000 person-years, 95% CI 4.3, 5.7 cases per 1000 person-years). Women with uterine fibroids were more likely to experience heavy or painful periods. They were also more likely to report low iron levels, endometriosis, and poor self-rated health and to have two or more annual visits to their general practitioner.
CONCLUSIONS: Our estimates are based on self-report of doctor diagnosis or treatment for fibroids and/or data linked to treatment and procedure administrative records. This predominantly captures women with symptomatic fibroids, but has the potential for misclassification of asymptomatic women and an underestimate of overall prevalence and incidence. In addition, questions on fibroids were only asked in surveys when women were 37-42 years of age to 43-48 years of age, so cases at younger ages may have been underestimated (particularly in women with less severe symptoms) as these were only ascertained through data linkage.
CONCLUSIONS: These are the first population-based estimates of the prevalence and incidence of uterine fibroids in women of reproductive age in Australia. Establishing these first estimates will help inform health policy and health care provision in the Australian context.
BACKGROUND: The ALSWH is funded by the Australian Government Department of Health and Aged Care. L.FW. was supported by an Australian National Health and Medical Research Council (NHMRC) Centres for Research Excellence grant (APP1153420) and G.D.M. was supported by an NHMRC Leadership Fellowship (APP2009577). The funding bodies played no role in the design, the collection, analysis or interpretation of data, the writing of the manuscript, or the decision to submit the manuscript for publication. There are no competing interests.
BACKGROUND: N/A.